ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Ginkgo Bioworks has signed an agreement to engineer up to four enzymes for use as biocatalysts in the manufacture of Merck & Co. active pharmaceutical ingredients. The biotech company aims to optimize the biocatalysts by employing proprietary fungal strains, cell line development, enzyme engineering, and multiomics expertise. Ginkgo claims its technology can expand the range of enzyme expression and reduce the cost of goods compared with standard Escherichia coli–hosted biocatalysis techniques. Ginkgo values the deal at up to $144 million.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X